Buprenorphine buccal - BioDelivery Sciences International
Alternative Names: BELBUCA; BEMA Buprenorphine; BEMA® LA; BEMA® Long Acting; Buprenorphine long acting; Buprenorphine transmucosal; EN 3409Latest Information Update: 10 Mar 2023
At a glance
- Originator BioDelivery Sciences International
- Developer BioDelivery Sciences International; Purdue Biopharma
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Pain
Most Recent Events
- 03 Mar 2023 Aquestive Therapeutics reached an agreement with BioDelivery Sciences for the commercialisation of buprenorphine buccal and buprenorphine/naloxone transmucosal drug film products in the US
- 22 Dec 2022 The Federal Circuit upholds judgment of the US district court for the District of Delaware regarding certain claims of patents protecting buprenorphine buccal
- 22 Mar 2022 BioDelivery Sciences International has been acquired by Collegium Pharmaceutical